39th week of 2018 patent applcation highlights part 10 |
Patent application number | Title | Published |
20180271910 | METHODS AND COMPOSITIONS FOR IMMUNOMODULATION - Provided are cells containing exogenous antigen and uses thereof. | 2018-09-27 |
20180271911 | INDUCED PLURIPOTENT STEM CELL DERIVED GLIAL ENRICHED PROGENITOR CELLS FOR THE TREATMENT OF WHITE MATTER STROKE - In various embodiments methods and compositions for improving a recovery of a subject after a cerebral ischemic injury, such as white matter stroke are provided. In certain embodiments, the methods involve administering human induced pluripotent glial enriched progenitor cells into the brain of the subject. | 2018-09-27 |
20180271912 | SPINAL DISC REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE - The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( | 2018-09-27 |
20180271913 | PHARMACEUTICAL COMPOSITIONS FOR PROMOTING HAIR FOLLICLE REGENERATION AND METHODS FOR PREPARING THE SAME - Pharmaceutical compositions for promoting hair follicle regeneration and their respective preparation methods are provided to overcome the ineffectiveness and low efficiency of the conventional hair follicle regeneration techniques. The methods for preparing the pharmaceutical compositions for promoting hair follicle regeneration include seeding dermal papilla cells and adipocyte lineage cells on a culture material in order for the dermal papilla cells and the adipocyte lineage cells to jointly assemble cell spheres. The pharmaceutical compositions can effectively enhance the effect and efficiency of hair follicle regeneration and thereby promote the regeneration of hair follicles. | 2018-09-27 |
20180271914 | Methods for Reducing the Extent of Light-induced Tissue Inflammation and Injury - The invention is directed to methods for reducing the extent of light-induced tissue injury. The method comprises applying a therapeutically effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) to the tissue prior to or as soon as possible following exposure to the light. In one particular example, the ACCS is applied within 90 minutes following exposure to the light. | 2018-09-27 |
20180271915 | AMNION DERIVED THERAPEUTIC COMPOSITION AND PROCESS OF MAKING SAME - Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells. | 2018-09-27 |
20180271916 | Treatment of diseases and conditions caused by increased vascular permeability - The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions). | 2018-09-27 |
20180271917 | USE OF UMBILICAL MESENCHYMAL STEM CELLS FOR TREATING PULMONARY FIBROSIS - The present invention relates to treatment of pulmonary fibrosis with umbilical mesenchymal stem cell. | 2018-09-27 |
20180271918 | BACTERIUM FOR USE AS A PROBIOTIC FOR NUTRITIONAL AND MEDICAL APPLICATIONS - A first aspect of the invention relates to the bacterial species | 2018-09-27 |
20180271919 | PROBIOTIC COMPOSITION AT LEAST COMPRISING BIFIDOBACTERIUM BIFIDUM W23 AND CAPABLE OF CONTROLLING INTESTINAL BARRIER FUNCTION - The disclosure relates to the field of medicine and nutrition, more specifically, to the field of treatment and prevention of human disorders such as depression, rumination, aggression, migraine, autistic spectrum disorders (including autism and ADHD), schizophrenia, chronic fatigue, kidney disorders, metabolic syndrome or diabetes type II. The disclosure provides a pharmaceutical or food composition or a supplement comprising a multispecies probiotic composition at least comprising | 2018-09-27 |
20180271920 | Probiotics And Methods Of Use - The present invention features methods for treating or reducing the severity of a microbial infection in an infant of a lactating mother. Compositions comprising food products fermented by | 2018-09-27 |
20180271921 | MODIFIED ONCOLYTIC VACCINIA VIRUSES EXPRESSING A CYTOKINE AND A CAR- BOXYLESTERASE AND METHODS OF USE THEREOF - The present disclosure pertains to a compositions and combinations for simultaneous, separate or sequential use which comprises (a) an oncolytic vaccinia virus that expresses a cytokine and a carboxylesterase enzyme, and, preferably, (b) a cancer co-drug, and to their uses for the treatment of cancer. | 2018-09-27 |
20180271922 | METHOD FOR REDUCING TOTAL GAS PRODUCTION AND/OR METHANE PRODUCTION IN A RUMINANT ANIMAL - The present invention relates to a method of reducing total gas production and/or methane production in a ruminant animal. | 2018-09-27 |
20180271923 | COMPOSITION FOR PREVENTING OR TREATING MENOPAUSAL DISORDERS, CONTAINING TETRAGONIA TETRAGONOIDES (PALL.) KUNTZE EXTRACT - The present invention relates to: a pharmaceutical composition for preventing or treating menopausal disorders, containing a | 2018-09-27 |
20180271924 | COMPOUND AND METHOD FOR REDUCING INFLAMMATION, PAIN, ALLERGY, FLU AND COLD SYMPTOMS - The present invention relates to pharmaceutical and nutraceutical compounds and methods for reducing inflammation, blood sugar, gastric acid, symptoms of allergy, common cold and flu, as well as treating infections and pain associated with trauma, medical procedure, and diseases and disorders in subjects in need thereof. The compounds and methods proposed by this invention are related to essentially a mixture of naturally accruing and/or synthetic substances in certain ratios, administration protocols, and delivery systems that amplify their medicinal qualities and reduce side effects, making their clinical application feasible. | 2018-09-27 |
20180271925 | Method For Improving Gingivitis And Periodontitis By Antibacterial, Antioxidant And Anti-Inflammatory Effects And Inhibition Of Alveolar Bone Loss Of Complex Extracts Of Moringa Leaf And Eucommia Bark - The present invention relates to a method for preventing, improving or treating a periodontal disease, by administering a composition containing a | 2018-09-27 |
20180271926 | USE OF TOMATO EXTRACT AS ANTIHYPERTENSIVE AGENT AND PROCESS FOR MAKING WATER SOLUBLE SUGAR FREE TOMATO EXTRACT - Provided herein is technology relating to tomato extracts and particularly, but not exclusively to preparing and using tomato extracts as an anti-hypertensive agent to modulate blood pressure. | 2018-09-27 |
20180271927 | BRAIN FUNCTION-PROTECTING AGENT - An object is to find out a safe component that can effectively exhibit action including the protection of a brain function, the prevention or alleviation of a reduction in cognitive ability, and the prevention or alleviation of dementia. A component of a plant body of a hybrid between | 2018-09-27 |
20180271928 | DIETARY SUPPLEMENT DERIVED FROM NATURAL PRODCUTS BY HOT MELT EXTRUSION (HME) PROCESSING - The invention provides a composition rich in flavonoids based on natural extracts, comprising a flavonoid extract dispersed by melt mixing or extrusion and encapsulated in a polymer matrix. The invention is also a novel dietary supplement with the naturally occurring ingredient (−)-epicatechin, cacao extracted, that could potentially prevent or reduce the risk of Atherosclerotic pathology. The use of (−)-epicatechin is promising as a therapeutic agent due to its potential antioxidant activity and its diverse biological properties. (−)-Epicatechins are chemically unstable and extensively degraded in fluids of near neutral or greater pH, such as intestinal juice and bile. Current technologies used for taste masking and modified release as spray drying, liposome entrapment, co-crystallization, freeze drying, among others, suffer from numerous shortcomings, including poor repeatability and limitations on target delivery. | 2018-09-27 |
20180271929 | Compositions and Methods for Identifying and Treating Dystonia Disorders - The present disclosure provides methods and compositions for the treatment, identification, diagnosis, and prognosis of dystonia, or dystonia related disorders. | 2018-09-27 |
20180271930 | METHOD FOR RAISING POULTRY - A method for raising poultry includes feeding poultry with a feed comprising oxidized glutathione during a period between hatching and 24 to 168 hours after the hatching. | 2018-09-27 |
20180271931 | P75NTR ANTAGONISTS AND TREATMENT OF ACUTE AND CHRONIC CARDIAC DISEASE - The present invention provides 75 kD transmembrane neurotrophin receptor (p75 | 2018-09-27 |
20180271932 | METHODS OF TREATING CELIAC DISEASE WITH LARAZOTIDE - The present invention provides compositions comprising Larazotide. The invention further provides methods of using the Larazotide compositions for treating celiac disease in symptomatic celiac disease patients. | 2018-09-27 |
20180271933 | ANTI-ANDROGEN PEPTIDES AND USES THEREOF IN CANCER THERAPY - The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (S1): X-[(Pro) | 2018-09-27 |
20180271934 | Methods of Treating Burns with i.v. cP12 in a Window from 2 to 6 Hours After Injury - A treatment window for the intravenous treatment of wounds, including thermal and chemical burns, with cP12 is presented. In particular, Applicants have unexpectedly found that delaying intravenous treatment with fibronectin-derived peptides, such as cP12, from 2 to 6 hours, particularly about 4 hours, after wounding, provides superior wound-closing results than treatment at 1 hour or after 8 or more hours. | 2018-09-27 |
20180271935 | DRALPHA1-MOG-35-55 TREATMENT OF TRAUMATIC BRAIN INJURY - Methods and compositions used in treating traumatic brain injury using a recombinant DRα-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DRα-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had a traumatic brain injury. | 2018-09-27 |
20180271936 | METHOD AND COMPOSITION FOR TREATMENT OF HAIR LOSS - A method of treating a hair loss condition, comprising administering a Notch signaling pathway activator to a subject in need thereof. | 2018-09-27 |
20180271937 | Use of Engrailed Proteins for Increasing Dopamine Synthesis by Dopaminergic Neurons - The invention relates to the use of an Engrailed protein as a medicament for increasing dopamine synthesis by dopaminergic neurons, in particular in the management of conditions associated with a decrease of dopamine levels without loss of dopaminergic neurons. | 2018-09-27 |
20180271938 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF - Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to kill or reduce the growth of microorganisms. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent microbial infection, or to improve a subject's heath or wellbeing. | 2018-09-27 |
20180271939 | GENETIC METHOD TO KILL CANCER CELLS BY SUFFOCATION - A genetic method to kill cancer by suffocation is presented. The invention involves directly administering a bacterial plasmid in the form of an expression vector to cancer cells or tissue in a patient with cancerous growth. The plasmid is in the form of an expression vector with a nucleic acid encoding the silk protein gene. | 2018-09-27 |
20180271940 | COMBINED PREPARATIONS FOR THE TREATMENT OF CANCER OR INFECTION - Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8 | 2018-09-27 |
20180271941 | METHODS FOR MODULATING DEVELOPMENT AND FUNCTION OF PHOTORECEPTOR CELLS - The present invention relates to compositions and methods comprising administering gene modifiers for treating ocular disease. | 2018-09-27 |
20180271942 | Use of the Insulin-Like-Growth Factor 1 Splice Variant MGF for the Prevention of Myocardial Damage - The invention relates to the use of a Mechano Growth Factor (MGF) polypeptide or a polynucleotide encoding an MGF polypeptide in the manufacture of a medicament for the prevention or limitation of myocardial damage in response to ischemia or mechanical overload of the heart by preventing or limiting apoptosis in the myocardium. | 2018-09-27 |
20180271943 | METHODS FOR TREATING INFLAMMATION WITH TGF-BETA - Provided wherein are methods for treating inflammation. In one embodiment, the method includes administering an effective amount of a composition to a subject having or at risk of having a condition that includes inflammation. The condition can be arthritis, tendonitis, osteoarthritis, fibrosis, shingles, psoriasis, acne, or dermatitis. Examples of dermatitis include atopic dermatitis, contact dermatitis, and seborrhoeic dermatitis. In one embodiment, the method includes administering an effective amount of a composition to a subject having pain, heat, and/or redness associated with inflammation. In one embodiment, the composition administered can include active TGF-β at a concentration of at least 0.001 nanograms/gram (ng/g). Optionally, the active TGF-β can be at a concentration of no greater than 4000 ng/g. | 2018-09-27 |
20180271944 | METHODS FOR TREATING DISEASES MEDIATED BY ERBB4-POSITIVE PRO-INFLAMMATORY MACROPHAGES - Provided herein are methods and compositions for treating disease-states associated with presence of increased number of ErbB4+ pro-inflammatory macrophages in a subject in need thereof. The methods include providing an activator of ErbB4 and administering a therapeutically effective amount of the activator to the subject. The compositions include an activator of ErbB4. In one embodiment, the activation of ErbB4 is Neuregulin-4. | 2018-09-27 |
20180271945 | UROCORTIN 2 ANALOGS AND USES THEREOF - Disclosed are polypeptides that are analogs of urocortin 2 that have pharmacological activity similar to urocortin 2 but have improved water solubility compared to urocortin 2, and pharmaceutical compositions of the polypeptides of the present invention. Also disclosed are polynucleotides encoding the polypeptides, and methods of treating pathophysiological states employing pharmaceutical compositions of the polypeptides and polynucleotides of the present invention. In addition, disclosed are vectors and host cells that include a nucleic acid encoding a polypeptide of the present invention, and kits that include pharmaceutical compositions of the present invention. | 2018-09-27 |
20180271946 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS - The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. | 2018-09-27 |
20180271947 | COAGONISTS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AND NEUROPEPTIDE Y2 RECEPTOR - Peptide sequences that can serve as agonists of both the glucagon-like peptide 1 receptor (GLP-IR) and the neuropeptide Y2 receptor (NPYR2). The peptide sequences include regions that correspond to certain aspect of natural substrates and known agonists of the glucagon-like peptide 1 receptor (GLP-IR) and the neuropeptide Y2 receptor (NPYR2) in a single sequence. | 2018-09-27 |
20180271948 | Methods for Producing Stable Therapeutic Glucagon Formulations in Aprotic Polar Solvents - Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent. | 2018-09-27 |
20180271949 | THERAPEUTIC TREATMENT FOR NEUROTROPHIC KERATOPATHY - The invention provides reagents, pharmaceutical compositions and methods for the treatment of prevention of disorders and diseases related to defects in trigeminal innervation of the cornea, stem cell deficiency, nonhealing epithelial wounds and particularly to diseases such as neurotrophic keratopathy. | 2018-09-27 |
20180271950 | USE OF FULL-LENGTH AMELOGENIN FOR PROMOTING NERVE GROWTH OR REGENERATION - A method of promoting nerve growth or regeneration in a subject in need thereof, wherein the subject is not afflicted with a substantial connective tissue damage, is provided. The method comprises administering to the subject a therapeutically effective amount of full-length amelogenin, thereby promoting nerve growth or regeneration in the subject. | 2018-09-27 |
20180271951 | METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY - The present invention relates in part to nucleic acids, including nucleic acids encoding proteins, therapeutics and cosmetics comprising nucleic acids, methods for delivering nucleic acids to cells, tissues, organs, and patients, methods for inducing cells to express proteins using nucleic acids, methods, kits and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, therapeutics, and cosmetics produced using these methods, kits, and devices. Methods and products for altering the DNA sequence of a cell are described, as are methods and products for inducing cells to express proteins using synthetic RNA molecules, including cells present in vivo. Therapeutics comprising nucleic acids encoding gene-editing proteins are also described. | 2018-09-27 |
20180271952 | Combination of Bactericidal Agent With a Lysosomotropic Alkalinising Agent for the Treatment of a Bacterial Infection - The present invention relates to the field of medicine, specifically the field of bacterial infection and treatment thereof. | 2018-09-27 |
20180271953 | ANTI-NET COMPOUNDS FOR TREATING AND PREVENTING FIBROSIS AND FOR FACILITATING WOUND HEALING - Embodiments of the technology described herein are based, in part, upon the discovery that NETosis, the formation of neutrophil extracellular traps (NETs) is increased in wounds, in organ fibrosis and in subjects with diabetes. Accordingly, methods for treating wounds, fibrosis and NET associated complications in diabetes are provided. The methods comprise administrating a therapeutically effective amount of at least one anti-NET compound to a subject in need of treatment, e.g. a PAD 4 inhibitor, a DNase, a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; an inhibitor of NET release, a protease inhibitor, or an elastase inhibitor. | 2018-09-27 |
20180271954 | TREATING CANCER WITH CAS ENDONUCLEASE COMPLEXES - The invention generally relates to compositions and methods for targeted delivery of a Cas endonuclease or nucleic acid encoding a Cas endonuclease to a fusion sequence in a cancer cell but not in a healthy cell of a subject. The Cas endonuclease or nucleic acid encoding the Cas endonuclease may be complexed with a guide RNA complementary to a fusion sequence identified based on differences between a mutated sequence obtained from a cancer cell and a wild-type sequence obtained from a healthy cell of the subject. For example, the Cas endonuclease may be a Cas9 and cut DNA or a Cas13a and cut RNA. The Cas endonuclease complexes may induce cell death or cancerous cells or cause other beneficial effects. | 2018-09-27 |
20180271955 | ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM - A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease. | 2018-09-27 |
20180271956 | METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS - A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease. | 2018-09-27 |
20180271957 | METHODS TO TREAT CEROID LIPOFUSCINOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS - A method to prevent, inhibit or treat one or more symptoms associated with a disease of the central nervous system by intrathecally, intracerebroventricularly or endovascularly administering a rAAV encoding a gene product associated with the disease, e.g., a mammal in which the gene product is absent or present at a reduced level relative to a mammal without the disease. | 2018-09-27 |
20180271958 | COMPOSITIONS AND METHODS FOR TREATMENT OF OCULAR DISEASES - Use of activated protein C (APC) for treatment and prevention of ocular diseases, disorders or conditions associated with retinal leakage and CNV such as age-related macular degeneration, optionally in combined therapy with anti-angiogenesis, anti-inflammatory, immunosuppressive, and anti PDGF agent. | 2018-09-27 |
20180271959 | SUSTAINED RELEASE POLOXAMER CONTAINING PHARMACEUTICAL COMPOSITIONS - A thermo-reversible thermoplastic pharmaceutical composition, comprising a botulinum toxin and a biocompatible poloxamer which provides thermoreversibility to the composition and additionally stabilizes the botulinum toxin, is described. The pharmaceutical composition can be administered to a patient as a liquid, and gels after administration into a sustained release drug delivery system from which the biologically active botulinum toxin is released over a multi-day period thereby localizing the drug as a depot and controlling release to enhance the therapeutic effect per dose. | 2018-09-27 |
20180271960 | METHOD TO TREAT CANCER USING ARGININE DELPETOR AND ORNITHINE DECARBOXYLASE (ODC) INHIBITOR - One example embodiment is a method of treating lung carcinoma in a subject in need thereof. The method includes administering to the subject a therapeutically effective amount of an arginine reducing compound and a therapeutically effective amount of an ornithine decarboxylase (ODC) inhibitor to provide a combination therapy that has a synergistic therapeutic effect compared to an effect of the arginine reducing compound and an effect of the ODC inhibitor, in which each of the arginine reducing compound and the ODC inhibitor is administered alone. | 2018-09-27 |
20180271961 | METHODS FOR INDUCING SELECTIVE APOPTOSIS - Provided herein are methods for cell therapy by modifying transfused cells to express an inducible caspase 9 protein, so that the cells may be selectively killed if the patient experiences dangerous side effects. Provided also within relates in part to methods for preventing or treating Graft versus Host Disease by modifying T cells before administration to a patient, so that they may be selectively killed if GvHD develops in the patient. | 2018-09-27 |
20180271962 | Peptide Conjugated Particles - The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance). | 2018-09-27 |
20180271963 | CANCER VACCINE FOR CATS - The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. | 2018-09-27 |
20180271964 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED TUMOUR ANTIGEN - The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(A) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the treatment of cancer or tumour diseases. The present invention further describes a method for increasing the expression of a peptide or protein comprising a tumour antigen or a fragment, variant or derivative thereof, using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal. | 2018-09-27 |
20180271965 | UTILIZATION OF RECOMBINANT INFLUENZA VIRUSES AND MODIFIED VACCINIA ANKARA VIRUS (MVA) WITH GENES THAT ENCODE FOR THE TOXOPLASMA GONDII SAG1 AND SAG2 SURFACE PROTEINS, AS VACCINES AGAINST TOXOPLASMOSIS - The present invention concerns to recombinant influenza viruses and modified Vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the | 2018-09-27 |
20180271966 | Live Attenuated Heterologous Vaccine for Leptospira - The present invention provides compositions or vaccines that contain a recombinant or an attenuated | 2018-09-27 |
20180271967 | OUTER MEMBRANE VESICLES AND USES THEREOF - The disclosure relates to outer membrane vesicles from | 2018-09-27 |
20180271968 | Conjunctivitis Vaccines - Compositions comprising antigenic peptides, and their use in inducing an immunoprotective response in a subject against an infection with | 2018-09-27 |
20180271969 | STREPTOCOCCUS SUIS POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION - The present invention relates to an immunogenic composition comprising polysaccharide-protein conjugates wherein each conjugate contains a capsular polysaccharide prepared from | 2018-09-27 |
20180271970 | RESPIRATORY SYNCYTIAL VIRUS VACCINE - The disclosure relates to respiratory syncytial virus (RSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. | 2018-09-27 |
20180271971 | ANTIGENS AND VACCINES DIRECTED AGAINST HUMAN ENTEROVIRUSES - The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an | 2018-09-27 |
20180271972 | DESIGN AND CHARACTERIZATION OF INFLUENZA VACCINES - Provided herein are optimized, recombinant influenza HA polypeptides that elicit immune responses. Also provided are compositions and kits comprising the optimized HA polypeptides as well as methods of making and using the optimized HA polypeptides. | 2018-09-27 |
20180271973 | COMPOSITIONS COMPRISING CH505 ENVELOPES, AND TRIMERS (EIGHT VALENT HIV-1 COMPOSITION AND METHODS) - In certain aspects the invention provides a selection of HIV-1 envelopes suitable for use as immunogens, and methods of using these immunogens in vaccination to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize. In other embodiments, the immunogens and methods of using these comprise an immune modulating component. | 2018-09-27 |
20180271974 | HERPES SIMPLEX VIRUS TYPE-1(HSV-1) VACCINE STRAIN VC2 GENERATING AN ANTI-EHV-1 IMMUNE RESPONSE - The disclosure encompasses recombinant nucleic acids comprising a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. Also provided is a live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. | 2018-09-27 |
20180271975 | HUMAN CYTOMEGALOVIRUS RNA VACCINES - The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. | 2018-09-27 |
20180271976 | METHODS FOR GENERATING NEUTRALIZING ANTI-PATHOGEN ANTIBODIES BY DIRECTING THE HUMORAL RESPONSE TOWARD DESIRED EPITOPES - Methods for generating antibodies to immuno-subdominant epitopes of elusive pathogens and vaccines and methods of vaccinating subjects against elusive pathogens are disclosed. The methods include targeting immunodominant B cells to undergo apoptosis, for example, while simultaneously targeting the germinal center (GC) reaction toward preferential selection and differentiation of B cells that produce broadly neutralizing antibody against a targeted pathogen. | 2018-09-27 |
20180271977 | METHODS RELATED TO TIM 3, A TH1-SPECIFIC CELL SURFACE MOLECULE, FOR ACTIVATING ANTIGEN PRESENTING CELLS - The present invention provides compositions and methods useful for promoting or reducing T-cell trafficking to a target tissue. Also provided are compositions and methods useful for promoting or inhibiting antigen-presenting cell (APC) activation. The invention is related to discovery of functional characteristics of TIM-3, a molecule that is preferentially expressed on the surface of Th1 cells. The methods are useful for treating disorders including cancer, infectious disease, allergy, asthma, and autoimmune disease. | 2018-09-27 |
20180271978 | BIOMATERIALS FOR COMBINED RADIOTHERAPY AND IMMUNOTHERAPY OF CANCER - Compositions and methods for the radiological and immunotherapeutic treatment of cancer are provided. Metallic nanoparticles conjugated with an immunoadjuvant are dispersed within a biodegradable polymer matrix that can be implanted in a patient and released gradually. The implant may be configured as, or be a component of, brachytherapy spacers and applicators, or radiotherapy fiducial markers. The composition may be combined with marginless radiotherapy, allowing for lower doses of radiation and enhancing the immune response against cancer, including at non-irradiated sites. | 2018-09-27 |
20180271979 | TRANS CAROTENOIDS, THEIR SYNTHESIS, FORMULATION AND USES - The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans. | 2018-09-27 |
20180271980 | DRUG DEVICE CONFIGURED FOR WIRELESS COMMUNICATION - This invention relates to an ingestible drug delivery device configured for wireless communication with other ingestible drug delivery devices. | 2018-09-27 |
20180271981 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM - Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as arthritis. | 2018-09-27 |
20180271982 | LIQUID PRODUCTS HAVING INCREASED SOLIDS CONCENTRATIONS - The present invention discloses liquid compositions that include an active compound, water, and means for inhibiting crystal formation or precipitation of the active compound in the liquid composition. | 2018-09-27 |
20180271983 | TRANSDERMAL CARRIER - Improved formulations for topical treatment that ensure at least localized transdermal or systemic delivery of an active agent through skin, nails or hair follicles are disclosed. | 2018-09-27 |
20180271984 | POLYLACTIDE COMPOSITIONS AND USES THEREOF - The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required. | 2018-09-27 |
20180271985 | Neurotherapeutic Nanoparticle Compositions Comprising Leukemia Inhibitory Factor - There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of: brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release. | 2018-09-27 |
20180271986 | GLYCOTARGETING THERAPEUTICS - Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein. | 2018-09-27 |
20180271987 | Controlled Cell Delivery Vehicle and Treatment of Tumours - The invention relates to apH mediated cell delivery vehicle comprising: a cargo or a cargo-binding molecule for binding to a cargo; a protein transduction domain; and a glycosaminoglycan (GAG) binding element, which is capable of binding to GAG on the surface of the cell, wherein the GAG binding element is a peptide which is modified to comprise one or more histidine residues which are capable of being protonated in an acidic environment. The invention further relates to the use of such a delivery vehicle including methods of treatment, such as treatment for cancer. | 2018-09-27 |
20180271988 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2018-09-27 |
20180271989 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2018-09-27 |
20180271990 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING - Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them. | 2018-09-27 |
20180271991 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS - The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells. | 2018-09-27 |
20180271992 | TREATMENT OF HIGH TROP-2 EXPRESSING TRIPLE NEGATIVE BREAST CANCER (TNBC) WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES HOMOLOGOUS RECOMBINATION REPAIR (HRR) RESCUE MEDIATED BY RAD51 - The present invention relates to treatment of Trop-2 positive cancers with the combination of anti-Trop-2 ADC and a Rad51 inhibitor. Preferably the drug conjugated to the antibody is SN-38, and the ADC is sacituzumab govitecan. The ADC may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the combination of ADC and Rad51 inhibitor can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the combination is effective to treat cancers that are refractory to or relapsed from irinotecan or topotecan. | 2018-09-27 |
20180271993 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY - Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described. | 2018-09-27 |
20180271994 | ANTI-MUC18 HUMAN IMMUNOTOXIN AND APPLICATIONS THEREOF - An anti-MUC18 immunotoxin including an anti-MUC18 single-chain variable fragment (scFv) with a nucleotide sequence as set forth in SEQ ID No. 3, and a truncated | 2018-09-27 |
20180271995 | A PROTEIN CONJUGATE COMPRISING MULTIPLE PHYSIOLOGICALLY ACTIVE POLYPEPTIDES AND AN IMMUNOGLOBULIN FC REGION - The present invention relates to a physiologically active polypeptide conjugate comprising multiple physiologically active polypeptides and immunoglobulin Fc regions, use thereof, and a preparation method thereof. | 2018-09-27 |
20180271996 | COMBINATION THERAPIES OF HER2-TARGETED ANTIBODY-DRUG CONJUGATES - Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications. | 2018-09-27 |
20180271997 | Methods and Reagents to Treat Tumor and Cancer - This disclosure provides reagent to treat tumor and cancer, and methods of using the same for treating tumor and cancer. One type of the reagent is pro-antibody, which is antibody that can be activated in tumor. Another type of the reagent is a conjugate of sialidase with affinity ligand that can bind to immuno cell surface or a conjugate of sialidase with affinity ligand that can bind to another antibody, therefore provide a sialidase based cancer immuno therapy strategy. | 2018-09-27 |
20180271998 | DISULFIDE-STABILIZED FABS - Provided are antibody fragments (Fabs) wherein native disulfide bonds are absent and engineered disulfide bonds have been introduced. Some fragments comprise further additional beneficial mutations. The fragments exhibit immuno specific binding and desirable stability properties, e.g., the fragments can be efficiently conjugated to effectors at high temperatures (e.g., >60° or >70° C.) without denaturing. | 2018-09-27 |
20180271999 | Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same - The present invention relates to an inclusion compound of fumagillol derivative or its salt with hydroxypropyl-β-cyclodextrin or sulfobutylether-7-β-cyclodextrin, and pharmaceutical compositions comprising the same. The inclusion compound according to the present invention has superior water solubility and stability while exhibiting low toxicity, rendering it valuable as an anticancer agent or inhibitor of tumor metastasis. | 2018-09-27 |
20180272000 | HOMOLOGOUS RECOMBINATION IN MULTIPOTENT ADULT PROGENITOR CELLS - The invention relates to methods of altering gene expression by homologous recombination in a multipotent adult progenitor cell (MAPC). In particular, methods of producing a recombinant MAPC, of correcting a genetic defect in a mammal, of providing a functional and/or therapeutic protein to a mammal, and of transforming a MAPC are provided. MAPCs containing an erogenous DNA as well as recombinant MAPCs and their differentiated progeny are also provided. | 2018-09-27 |
20180272001 | ANTI-CANCER AND ANTI-INFLAMMATORY THERAPEUTICS AND METHODS THEREOF - The invention relates to the discovery of a vital new component of the Wnt pathway that regulates trafficking of β-catenin to the cell nucleus and novel therapeutic approaches to cancer treatment. Disclosed herein is a previously unknown, essential component of the Wnt/β-catenin signaling pathway that governs the quantity of β-catenin delivered to the cell nucleus. This intracellular inhibitor of β-catenin signaling (IBS) is transcribed from a second transcriptional start site adjacent to exon 3 of the Dkk3 gene and is required for early mouse development. IBS captures β-catenin destined for the nucleus in a complex with β-TrCP that is bound to the actin cytoskeleton and unavailable for nuclear translocation. | 2018-09-27 |
20180272002 | Biodegradable Lipids for Delivery of Nucleic Acids - The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R | 2018-09-27 |
20180272003 | Biodegradable Lipids for Delivery of Nucleic Acids - The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R | 2018-09-27 |
20180272004 | Biodegradable Lipids for Delivery of Nucleic Acids - The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R | 2018-09-27 |
20180272005 | Biodegradable Lipids for Delivery of Nucleic Acids - The present invention provides, in part, a biodegradable compound of formula I, and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof, where each X independently is O or S, each Y independently is O or S, and each R | 2018-09-27 |
20180272006 | Diabetes Gene Therapy - There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional preproinsulin protein wherein the nucleotide sequence has at least 86% identity to the sequence of SEQ ID NO. 1. Also described are: vectors comprising the nucleic acid molecule for expressing the preproinsulin protein; host cells comprising the nucleic acid molecule or a vector; a transgenic animal comprising cells comprising the nucleic acid molecule or the vector; a pharmaceutical composition comprising the nucleic acid molecule or the vector; a method of treating diabetes comprising administering a therapeutically effective amount of the vector to a patient suffering from diabetes; the nucleic acid molecule for use in therapy; and the nucleic acid molecule or the vector for use in the treatment of diabetes. | 2018-09-27 |
20180272007 | LONG POLY(A) PLASMIDS AND METHODS FOR INTRODUCTION OF LONG POLY(A) SEQUENCES INTO THE PLASMID - Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide. | 2018-09-27 |
20180272008 | NANOALLERGENS AND USES THEREOF - Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test. | 2018-09-27 |
20180272009 | NON-HUMAN PRIMATE MODEL OF AGE-RELATED MACULAR DEGENERATION AND METHOD FOR PRODUCING SAME - An object of the present invention is to provide a method for producing a non-human primate model of AMD, a method for evaluating the efficacy of a test substance in the prevention or treatment of AMD using the AMD animal model produced according to this method, and a method for screening substances effective in the prevention or treatment of AMD using the aforementioned AMD animal model. The method for preparing the AMD animal model consists of administering sodium iodate into a vitreous body of a non-human primate, and the method for evaluating the efficacy of a test substance in the prevention or treatment of AMD consists of preparing a non-human primate model of AMD according to the aforementioned method for preparing an AMD animal model, and evaluating the efficacy of the test substance in the prevention or treatment of AMD using the resulting AMD animal model. | 2018-09-27 |